TerminatedPhase 2NCT01886287
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
Studying Carcinoid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Principal Investigator
- Jonathan Strosberg, M.D., MDH. Lee Moffitt Cancer Center and Research Institute
- Intervention
- Octreotide LAR(drug)
- Enrollment
- 2 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2014
Study locations (1)
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Collaborators
Novartis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01886287 on ClinicalTrials.govOther trials for Carcinoid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07087054Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenCrinetics Pharmaceuticals Inc.
- RECRUITINGNCT05756608Fibrosis in Chronic and Delayed Myocardial InfarctionUniversity of Edinburgh
- ACTIVE NOT RECRUITINGNANCT05064514Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart DiseaseQueen Mary University of London
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT04993261An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid TumorsM.D. Anderson Cancer Center